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Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are rare conditions associated with a poor prognosis, for which treatments are expensive and, at best, only moderately efficacious. Until the very latest stages of disease progression, symptoms occur almost exclusively with physical exertion, most probably reflecting insufficient oxygen delivery to peripheral muscles caused through limitations of right ventricular (RV) reserve relative to heightened pulmonary vascular afterload. 1 Despite this, assessments are most frequently performed at rest. In this issue of the journal, Blumberg and colleagues 2 remind us that resting measures may be an inadequate surrogate of the pathophysiology of pulmonary hypertension when assessed during exercise. They performed cardiopulmonary testing and cardiac catheterization at rest and during exercise in 21 PAH and 15 CTEPH patients, and observed a modest correlation between cardiac index during exercise and maximal oxygen uptake (peakVO 2 ). This is not greatly surprising as cardiac output is known to explain the majority of variance in VO 2 in health and disease 3 -put simply, if the blood cannot get to the muscles then it cannot be utilized. Of greater interest is the finding that the strongest predictors of survival were all obtained during exercise. Peak cardiac index and the pressure/flow relationship (analogous to the change in pulmonary vascular resistance) both predicted survival (61% at 5 years), while the strongest predictors were the non-invasively determined measures of peakVO 2 and ventilatory efficiency (VE/VCO 2 ). These findings are consistent with previous experience. In a larger cohort, Wensel et al. 4 demonstrated that peakVO 2 was a strong predictor of survival in patients with PAH, especially when systolic blood pressure failed to increase during exercise. As compared with cardiopulmonary testing, a 6 min walk distance (6MWD) is a simpler measure of exercise capacity that may be nearly as accurate in predicting patient outcomes. 5 Partly as a result of this simplicity, the 6MWD has been adopted as the primary endpoint for multiple clinical trials investigating the efficacy of various pulmonary vasodilators. This would seem reasonable given that 6MWD is a practical description of functional capacity (an important treatment goal) and the correlation between 6MWD and survival suggests utility as a surrogate of improved patient outcomes. However, recent analyses of pooled PAH patient data suggest that the 6MWD fails on both counts, 6, 7 leaving us to ask why. The agreement between 6MWD and peakVO 2 is relatively poor, 8 and perhaps the 6MWD is just too blunt a measure to detect meaningful differences in exercise capacity after only 3-4 months of therapy. Blumberg et al. did not assess 6MWD, but their data would suggest that well-performed exercise measures should not be dismissed. On the contrary, cardiopulmonary and haemodynamic measures were only of prognostic value when measured during exercise and thus we may conclude that the goal should be to sharpen our exercise measures further. If surrogate measures are to be chosen as endpoints in PAH trials, then it is clearly desirable that they offer an insight into the pathophysiology of the condition and the mechanism of therapeutic effect. 9 In this regard, the methodologies described by Blumberg Figure 1 ). 2 remind us of the importance of studying our patients during exercise, when symptoms and physiological limitations are most appreciable. Their data challenge us to assess whether more accurate exercise measures will provide even greater insights into the pathophysiology of PAH and more specific measures against which treatment efficacy may be assessed.
Conflict of interest: none declared. Figure 1 Real-time exercise cardiac magnetic resonance imaging demonstrating increasing right ventricular dilation and dysfunction during exercise in a patient with pulmonary hypertension. Shortaxis images acquired at a mid-ventricular level in a subject with chronic thrombo-embolic pulmonary hypertension describing profound breathlessness and pre-syncope with exertion. End-systolic images demonstrate a moderately dilated right ventricle with mild systolic dysfunction at rest (upper panel) becoming more dilated during near-maximal exercise (lower), resulting in filling impairment of the left ventricle and markedly attenuating increases in cardiac output. Thus, as compared with rest, the exercise pathophysiology better explains the severity of the symptoms.
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